» Articles » PMID: 28678391

Interferon Lambda1/IL-29 and Inorganic Polyphosphate Are Novel Regulators of Neutrophil-driven Thromboinflammation

Abstract

Neutrophils and neutrophil-released meshwork structures termed neutrophil extracellular traps (NETs) are major mediators of thromboinflammation and emerging targets for therapy, yet the mechanisms and pathways that control the role of neutrophils in thromboinflammation remain poorly understood. Here, we explored the role of IFN-λ1/IL-29, a major antiviral cytokine recently shown to suppress the neutrophil migratory capacity, in prothrombotic and proNETotic functions of neutrophils. In an ex vivo human experimental setting of acute ST-segment elevation myocardial infarction (STEMI), we show that IFN-λ1/IL-29 hinders NET release and diminishes the amount of cytoplasmic TF in neutrophils. Since platelet-neutrophil interaction plays a major role in NET-induced thromboinflammation, we further studied how IFN-λ1/IL-29 may interrupt this interaction. In this context, we identified inorganic polyphosphate (polyP) as a platelet-derived NET inducer in STEMI. In arterial STEMI thrombi, polyP was present in platelets and in close proximity to NET remnants. PolyP release from activated platelets was dependent on thrombin present in infarcted artery plasma, resulting in NET formation by promoting mTOR inhibition and autophagy induction. The effect of polyP on mTOR inhibition was counteracted by IFN-λ1/IL-29 treatment, leading to inhibition of NET formation. Consistently, we show in an in vivo model of FeCl -induced arterial thrombosis that IFN-λ2/IL-28A exerts strong antithrombotic potential. Taken together, these findings reveal a novel function of IFN-λ1/IL-29 in the suppression of thromboinflammation. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Citing Articles

Proceedings of the 1st Symposium "Autoimmune Diseases: Clinical Unmet Needs in Systemic Autoimmune Diseases Guide Clinical, Translational and Basic Research".

Chatzis L, Koutsogianni A, Palla P, Palamidas D, Panagopoulos P, Maria P Mediterr J Rheumatol. 2025; 35(4):692-703.

PMID: 39886294 PMC: 11778608. DOI: 10.31138/mjr.121124.pts.


Interferon lambda signaling in neutrophils enhances the pathogenesis of Bordetella pertussis infection.

Kumar A, Johnson D, Bukowski A, Noto M, Carbonetti N J Leukoc Biol. 2024; 117(2).

PMID: 39302155 PMC: 11879762. DOI: 10.1093/jleuko/qiae202.


Immunothrombosis: A bibliometric analysis from 2003 to 2023.

Hou M, Wu J, Li J, Zhang M, Yin H, Chen J Medicine (Baltimore). 2024; 103(37):e39566.

PMID: 39287275 PMC: 11404911. DOI: 10.1097/MD.0000000000039566.


Shared Genetic Features of Psoriasis and Myocardial Infarction: Insights From a Weighted Gene Coexpression Network Analysis.

Zhou Q, Shi R J Am Heart Assoc. 2024; 13(7):e033893.

PMID: 38533976 PMC: 11179746. DOI: 10.1161/JAHA.123.033893.


Interferon lambda in respiratory viral infection: immunomodulatory functions and antiviral effects in epithelium.

Liu Y, Jin S, Zhang S, Xia T, Liao Y, Pan R Front Immunol. 2024; 15:1338096.

PMID: 38495892 PMC: 10940417. DOI: 10.3389/fimmu.2024.1338096.